Olivia R. Ringham

Olivia R. Ringham

Auto-generated profile, based on publicly available information

Olivia R. Ringham

Department of Microbiology & Immunology, Columbia University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KKKatherine A. Kaiser
Katherine A. Kaiser
LLLucas F. Loffredo
Lucas F. Loffredo
KSKenia de Los Santos-Alexis
Kenia de Los Santos-Alexis
OROlivia R. Ringham
Olivia R. Ringham
NANicholas Arpaia
Nicholas Arpaia
Following respiratory viral infection, regeneration of the epithelial barrier is required to preserve lung function and prevent secondary infections. Lung regulatory T (Treg) cells are critical for maintaining blood oxygenation following influenza virus infection through production of the EGFR ligand amphiregulin (Areg); however, how Treg cells engage with progenitors within the alveolar niche is unknown. Here, we describe local interactions between Treg cells and an Areg-responsive population of Col14a1+EGFR+ lung mesenchymal cells that mediate type II alveolar epithelial (AT2) cell-mediated regeneration following influenza virus infection. We propose a mechanism whereby Treg cells are deployed to sites of damage and provide pro-survival cues that support mesenchymal programming of the alveolar niche. In the absence of fibroblast EGFR signaling, we observe impaired AT2 proliferation and disrupted lung remodeling following viral clearance, uncovering a crucial immune/mesenchymal/epithelial network that guides alveolar regeneration.

26 April 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LLLucas F. Loffredo
Lucas F. Loffredo
TSThomas M. Savage
Thomas M. Savage
OROlivia R. Ringham
Olivia R. Ringham
NANicholas Arpaia
Nicholas Arpaia
Regulatory T (Treg) cells are classically known for their critical immunosuppressive functions that support peripheral tolerance. More recent work has demonstrated that Treg cells produce pro-repair mediators independent of their immunosuppressive function, a process that is critical to repair and regeneration in response to numerous tissue insults. These factors act on resident parenchymal and structural cells to initiate repair in a tissue-specific context. This review examines interactions between Treg cells and tissue-resident non-immune cells—in the context of tissue repair, fibrosis, and cancer—and discusses areas for future exploration.

15 August 2022 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
PWPeter H. Wang
Peter H. Wang
RWRobert Washburn
Robert Washburn
RMRohan Maniar
Rohan Maniar
MMMichael Mu
Michael Mu
OROlivia Ringham
Olivia Ringham
SRSteven L. Reiner
Steven L. Reiner
Immune checkpoint blockade is limited by resistance to treatment, with many patients not achieving durable antitumor responses. Self-renewing (T cell factor 1+ [TCF1+]) CD8+ T cells have recently been implicated in efficacy of anti–programmed cell death protein 1 (anti–PD-1). Mice challenged with syngeneic tumors were treated with anti–PD-1 and/or a reversible inhibitor of PI3K δ, designed to promote T cell self-renewal. Growth of tumors in untreated mice was characterized by waning proportions of TCF1+ T cells, suggesting self-renewing T cells become limiting for successful immunotherapy. Higher proportions of TCF1+ T cells in tumor and blood correlated with better control of tumor growth. Combining anti–PD-1 and inhibitor of PI3K δ conferred superior protection compared with either monotherapy and was associated with higher frequency of TCF1+ T cells in tumor and blood compared with anti–PD-1 alone. These findings reveal predictive importance of self-renewing T cells in anti-tumor immunity and suggest that resistance-directed strategies to enhance T cell self-renewal could potentiate the efficacy of PD-1 blockade.

1 May 2023 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
LLLucas F Loffredo
Lucas F Loffredo
FLFangda Li
Fangda Li
OROlivia R Ringham
Olivia R Ringham
ASAnmol Surpur
Anmol Surpur
RCRenzo Cavero
Renzo Cavero
NANicholas Arpaia
Nicholas Arpaia
Heparan sulfate (HS), a glycan subtype, is ubiquitously present on the surface of structural tissue cells and tumor cells during homeostasis, disease, and cancer, but how it affects immune cell trafficking, activation, and signal transmission in these tissue contexts is poorly understood. Furthermore, amphiregulin (Areg), a growth factor used by immune cells for intercommunication with structural tissue and tumor cells, contains a HS binding domain. We investigated the downstream signaling modalities of Areg-mediated cell activation in the context of HS inhibition. Areg signaling is qualitatively altered, but still present, upon exogenous inhibition or genetic ablation of HS. We further probed the consequences of HS-dependent vs. -independent Areg signaling at the transcriptional level. Next, we used a panel of CRISPR-Cas9-mediated knockout Lewis Lung Carcinoma (LLC) cell lines to interrogate how various aspects of HS (core proteoglycan, HS chain extension, sulfation status) contribute to Areg signaling. We found that the presence of the glypican family of HS-harboring proteoglycans on the surface of cells is critical for Areg signaling. Lastly, we explored the effects of cancer cell HS on immune system trafficking to and activation within tumors. HS-deficient tumors experience similar levels of lymphoid cell trafficking and activation, but show a significant increase in the presence of certain myeloid cell type (neutrophils, monocytes, and macrophages). Additionally, tumor-associated macrophages within HS-deficient tumors show an altered phenotype, with increased maturation markers. Overall, our work has illuminated previously understudied aspects of the relationships between HS, Areg, and the immune system. Supported by a grant from NIH (R21-AI149657)

28 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LLLucas F. Loffredo
Lucas F. Loffredo
ASAnmol Surpur
Anmol Surpur
OROlivia R. Ringham
Olivia R. Ringham
FLFangda Li
Fangda Li
KSKenia de Los Santos-Alexis
Kenia de Los Santos-Alexis
NANicholas Arpaia
Nicholas Arpaia
Amphiregulin (Areg), a growth factor produced by regulatory T (Treg) cells to facilitate tissue repair/regeneration, contains a heparan sulfate (HS) binding domain. How HS, a highly sulfated glycan subtype that alters growth factor signaling, influences Areg repair/regeneration functions is unclear. Here we report that inhibition of HS in various cell lines and primary lung mesenchymal cells (LMC) qualitatively alters downstream signaling and highlights the existence of HS-dependent vs. -independent Areg transcriptional signatures. Utilizing a panel of cell lines with targeted deletions in HS synthesis–related genes, we found that the presence of the glypican family of heparan sulfate proteoglycans is critical for Areg signaling and confirmed this dependency in primary LMC by siRNA-mediated knockdown. Furthermore, in the context of influenza A (IAV) infection in vivo , we found that an Areg-responsive subset of reparative LMC upregulate glypican-4 and HS. Conditional deletion of HS primarily within this LMC subset resulted in reduced blood oxygen saturation following infection with IAV, with no changes in viral load. Finally, we found that co-culture of HS-knockout LMC with IAV-induced Treg cells results in reduced LMC responses. Collectively, this study reveals the essentiality of HS on a specific lung mesenchymal population as a mediator of Treg cell–derived Areg reparative signaling during IAV infection.